Molecular Modeling of Benzothiazepine Binding in the L-type Calcium Channel*

Benz(othi)azepine (BTZ) derivatives constitute one of three major classes of L-type Ca2+ channel ligands. Despite intensive experimental studies, no three-dimensional model of BTZ binding is available. Here we have built KvAP- and KcsA-based models of the Cav1.2 pore domain in the open and closed states and used multiple Monte Carlo minimizations to dock representative ligands. In our open channel model, key functional groups of BTZs interact with BTZ-sensing residues, which were identified in previous mutational experiments. The bulky tricyclic moiety occupies interface between domains III and IV, while the ammonium group protrudes into the inner pore, where it is stabilized by nucleophilic C-ends of the pore helices. In the closed channel model, contacts with several ligand-sensing residues in the inner helices are lost, which weakens ligand-channel interactions. An important feature of the ligand-binding mode in both open and closed channels is an interaction between the BTZ carbonyl group and a Ca2+ ion chelated by the selectivity filter glutamates in domains III and IV. In the absence of Ca2+, the tricyclic BTZ moiety remains in the domain interface, while the ammonium group directly interacts with a glutamate residue in the selectivity filter. Our model suggests that the Ca2+ potentiation involves a direct electrostatic interaction between aCa2+ ion and the ligand rather than an allosteric mechanism. Energy profiles indicate that BTZs can reach the binding site from the domain interface, whereas access through the open activation gate is unlikely, because reorientation of the bulky molecule in the pore is hindered.

[1]  W. Stühmer,et al.  Calcium channel characteristics conferred on the sodium channel by single mutations , 1992, Nature.

[2]  H. L. Yale The trifluoromethyl group in medicinal chemistry. , 1959, Journal of medicinal and pharmaceutical chemistry.

[3]  K. Seydl,et al.  The benzazepine/benzothiazepine binding domain of the cardiac L-type Ca2+ channel is accessible only from the extracellular side , 1993, Pflügers Archiv.

[4]  H. Scheraga,et al.  Monte Carlo-minimization approach to the multiple-minima problem in protein folding. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Breithardt,et al.  Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1. , 2003, Molecular pharmacology.

[6]  J. Hume,et al.  Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells , 1985, The Journal of general physiology.

[7]  W. Almers,et al.  Non‐selective conductance in calcium channels of frog muscle: calcium selectivity in a single‐file pore. , 1984, The Journal of physiology.

[8]  M. Lazdunski,et al.  Characterization of the Ca2+ coordination site regulating binding of Ca2+ channel inhibitors d-cis-diltiazem, (+/-)bepridil and (-)desmethoxyverapamil to their receptor site in skeletal muscle transverse tubule membranes. , 1985, Biochemical and biophysical research communications.

[9]  Leonor Saiz,et al.  Computer simulation studies of model biological membranes. , 2002, Accounts of chemical research.

[10]  N. Dilmac,et al.  Molecular Determinants of Frequency Dependence and Ca2+ Potentiation of Verapamil Block in the Pore Region of Cav1.2 , 2004, Molecular Pharmacology.

[11]  R. MacKinnon,et al.  Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors , 2001, Nature.

[12]  T. Nagao,et al.  High-affinity binding of [3H]DTZ323 to the diltiazem-binding site of L-type Ca2+ channels. , 2003, European journal of pharmacology.

[13]  B. Zhorov,et al.  KvAP-based model of the pore region of shaker potassium channel is consistent with cadmium- and ligand-binding experiments. , 2005, Biophysical journal.

[14]  P. Kollman,et al.  An all atom force field for simulations of proteins and nucleic acids , 1986, Journal of computational chemistry.

[15]  C. Strübing,et al.  Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels. , 1993, Molecular pharmacology.

[16]  P. Focia,et al.  Structural basis of TEA blockade in a model potassium channel , 2005, Nature Structural &Molecular Biology.

[17]  D. Himmel,et al.  Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. , 1988, The Journal of biological chemistry.

[18]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[19]  H. Ichijo,et al.  Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists. , 2003, Molecular pharmacology.

[20]  V. Ananthanarayanan,et al.  Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists. , 2001, Archives of biochemistry and biophysics.

[21]  Boris S. Zhorov,et al.  A vector method for calculating the derivatives of the energy of the atom-atom interactions of complex molecules with respect to generalized coordinates , 1981 .

[22]  J. Das,et al.  Benzazepinone calcium channel blockers. 3. Synthesis and structure-activity studies of 3-alkylbenzazepinones. , 1992, Journal of medicinal chemistry.

[23]  H. Glossmann,et al.  Sequence Differences between α1C and α1S Ca2+ Channel Subunits Reveal Structural Determinants of a Guarded and Modulated Benzothiazepine Receptor* , 1999, The Journal of Biological Chemistry.

[24]  H. Fozzard,et al.  Modeling of the outer vestibule and selectivity filter of the L-type Ca2+ channel. , 2001, Biochemistry.

[25]  Molecular Mechanism of Diltiazem Interaction with L-type Ca2+ Channels* , 1998, The Journal of Biological Chemistry.

[26]  T. Linn,et al.  Temperature‐dependent regulation of d‐cis‐[3H]diltiazem binding to Ca2+ channels by 1,4‐dihydropyridine channel agonists and antagonists , 1983, FEBS Letters.

[27]  W. Almers,et al.  The Ca channel in skeletal muscle is a large pore. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Grissmer,et al.  Investigation of the Phenylalkylamine Binding Site in hKv1.3 (H399T), a Mutant with a Reduced C-Type Inactivated State , 2005, Molecular Pharmacology.

[29]  N. Dilmac,et al.  Molecular determinants of Ca2+ potentiation of diltiazem block and Ca2+-dependent inactivation in the pore region of cav1.2. , 2003, Molecular pharmacology.

[30]  G. Kaczorowski,et al.  Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors. , 1986, The Journal of biological chemistry.

[31]  J. Das,et al.  Benzazepinone calcium channel blockers. 5. Effects on antihypertensive activity associated with N1 and aromatic substituents. , 1992, Journal of medicinal chemistry.

[32]  B. Zhorov,et al.  Atomic determinants of state‐dependent block of sodium channels by charged local anesthetics and benzocaine , 2006, FEBS letters.

[33]  M. Cadene,et al.  X-ray structure of a voltage-dependent K+ channel , 2003, Nature.

[34]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[35]  M. Karplus,et al.  Effective energy function for proteins in solution , 1999, Proteins.

[36]  Ming Zhou,et al.  A mutant KcsA K(+) channel with altered conduction properties and selectivity filter ion distribution. , 2004, Journal of molecular biology.

[37]  W. Catterall,et al.  Molecular determinants of drug binding and action on L-type calcium channels. , 1997, Annual review of pharmacology and toxicology.

[38]  H. Lüllmann,et al.  Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists. , 1992, Pharmacology & toxicology.

[39]  I. Findlay Physiological modulation of inactivation in L‐type Ca2+ channels: one switch , 2004, The Journal of physiology.

[40]  J. Das,et al.  Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. , 1992, Journal of medicinal chemistry.

[41]  Ettore Novellino,et al.  Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations. , 2007, Journal of medicinal chemistry.

[42]  Benoît Roux,et al.  A gate in the selectivity filter of potassium channels. , 2005, Structure.

[43]  R. Tsien,et al.  Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells , 1983, Nature.

[44]  H. Fozzard,et al.  Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. , 2003, Molecular pharmacology.

[45]  G. Yellen,et al.  Intracellular gate opening in Shaker K+ channels defined by high-affinity metal bridges , 2004, Nature.

[46]  Boris S Zhorov,et al.  Sodium channels: ionic model of slow inactivation and state-dependent drug binding. , 2007, Biophysical journal.

[47]  B. Hille,et al.  Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.

[48]  H. Fozzard,et al.  μ-Conotoxin Giiia Interactions with the Voltage-Gated Na+ Channel Predict a Clockwise Arrangement of the Domains , 2000, The Journal of general physiology.

[49]  J. Das,et al.  Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. , 1992, Journal of medicinal chemistry.

[50]  N. Soldatov,et al.  Molecular Determinants of Voltage-dependent Slow Inactivation of the Ca2+ Channel* , 2002, The Journal of Biological Chemistry.

[51]  B. Zhorov,et al.  Potassium, sodium, calcium and glutamate‐gated channels: pore architecture and ligand action , 2004, Journal of neurochemistry.

[52]  B. Zhorov,et al.  Modeling P-loops domain of sodium channel: homology with potassium channels and interaction with ligands. , 2005, Biophysical journal.

[53]  Daniel Borgis,et al.  A coarse-grained protein-protein potential derived from an all-atom force field. , 2007, The journal of physical chemistry. B.

[54]  S. Spergel,et al.  1-Benzazepin-2-one calcium channel blockers--VI. Receptor-binding model and possible relationship to desmethoxyverapamil. , 1993, Bioorganic & medicinal chemistry.

[55]  Thomas Huber,et al.  G protein-coupled receptors self-assemble in dynamics simulations of model bilayers. , 2007, Journal of the American Chemical Society.

[56]  T. Nagao,et al.  1,5-benzothiazepine binding domain is located on the extracellular side of the cardiac L-type Ca2+ channel. , 1997, Molecular pharmacology.

[57]  S. Grissmer,et al.  Interaction of d-Tubocurarine with Potassium Channels: Molecular Modeling and Ligand Binding , 2006, Molecular Pharmacology.